HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e15014
Abstract: e15014 Background: Prestige Biopharma Pte Ltd is developing HD204, a biosimilar of the EU-approved and US-licensed Bevacizumab (Avastin) that is approved treatment for a variety of tumour types. Bevacizumab is a recombinant humanized monoclonal antibody… read more here.
Keywords: hd204 analytical; biocomparability clinical; biocomparability; analytical biocomparability ... See more keywords
Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.
Sign Up to like & getrecommendations! Published in 2017 at "Arquivos brasileiros de oftalmologia"
DOI: 10.5935/0004-2749.20170026
Abstract: Purpose: Avastin® (bevacizumab) is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody given as an off-label drug by intravitreal administration for treatment of ocular diseases. The drug's clinical application and its cost-benefit profile has generated… read more here.
Keywords: avastin; bevacizumab; use; glass vials ... See more keywords